|View printer-friendly version|
|Medtronic Launches Lower-Extremity Indication for Complete ‘SE’ Vascular Stent Internationally|
Self-Expanding Peripheral Device Gets CE Mark for Superficial Femoral and Proximal Popliteal Arteries
MINNEAPOLIS –– Jan. 24, 2013 –– Expanding its role in the treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced the CE (Conformité Européene) mark and international launch of its Complete SE (self-expanding) vascular stent for use in the lower extremities –– specifically, the superficial femoral arteries (SFA) and proximal popliteal arteries (PPA), which supply blood to the legs.
In the United States, the Complete SE stent is approved by the U.S. Food and Drug Administration (FDA) only for use in the iliac arteries, which supply blood to the pelvis and legs. Its use in lower-extremity arteries in the United States is under review by the FDA. Previously CE marked only for use in the iliac arteries, the Complete SE stent can now be used internationally in the lower extremities as well.
The new indication was obtained after clinical data from the Complete SE SFA study –– an independently adjudicated single-arm, multicenter trial that enrolled 196 patients at 28 sites in the United States and Europe –– showed a low clinically-driven target lesion revascularization (i.e. repeat procedure) rate of 8.4 percent at 12 months. Additionally, and unique among similar studies utilizing bare-metal stents in this vessel bed, there were no (0.0 percent) stent fractures at 12 months in the study.
These outcomes were achieved despite the challenging nature of the patient population represented:
The Complete SE SFA study showed statistically significant improvements in multiple measures of clinical and functional effectiveness:
“The Complete SE stent not only delivers compelling clinical results, but its unique features and delivery system offer an ease-of-use unparalleled with other devices designed to treat lower-extremity lesions,” said Prof. Dierk Scheinert, chairman of the Center for Vascular Medicine at Part Hospital in Leipzig, Germany.
With risk factors including smoking, diabetes, obesity, high blood pressure, high cholesterol, age (50 or older) and familial history, peripheral artery disease narrows the vessels that supply blood to the body, especially the limbs. Typically characterized by an excessive buildup of plaque in these vessels, the condition can progress without treatment to critical limb ischemia, which often leads to amputation and premature death.
A variety of treatments are used to restore normal blood flow in patients with peripheral artery disease. Stents are metallic scaffolds used to improve blood flow by expanding the interior diameter of narrowed arteries. They are implanted in a minimally invasive procedure that uses catheters to access the arterial segment requiring treatment.
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
– end –
Medtronic Media Contacts:
Joe McGrath, Public Relations, 707-591-7367
Jeff Warren, Investor Relations, 763-505-2696